Internal Medicine, Nephrology · Portland, OR
NPI
1467478289
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
10201 SE Main St Ste 27
Portland, OR, 97216
Phone (503) 256-0877
Groups this clinician bills Medicare through
Medicare paid, 2024
$92K
1,551 services
Medicare patients, 2024
224
Average age 69
Drug cost, 2024
$321K
2,426 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Julie Raggio was code Q5106 (injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units), 586 times for 11 patients. In total Julie Raggio billed 1,551 services in 29 codes, and Medicare paid $92K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 586 | 11 | $5.49 | $3,217 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 155 | 85 | $11.97 | $1,855 |
| 99233 Hospital E&M - Subsequent | Facility | 150 | 63 | $92.78 | $14K |
| 90960 ESRD Related Services (not dialysis) | Office | 113 | 21 | $280.77 | $32K |
| 99214 Office E&M - Established | Office | 96 | 68 | $61.00 | $5,856 |
| 99215 Office E&M - Established | Office | 87 | 53 | $82.79 | $7,203 |
| 85018 Blood Count | Office | 41 | 12 | $2.13 | $87.4 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 40 | 16 | $48.46 | $1,938 |
| 99232 Hospital E&M - Subsequent | Facility | 36 | 23 | $58.63 | $2,111 |
| 96372 Injection Administration | Office | 34 | 11 | $10.77 | $366 |
| 99222 Hospital E&M - Initial | Facility | 32 | 30 | $96.33 | $3,083 |
| 99213 Office E&M - Established | Office | 27 | 24 | $34.98 | $944 |
| 90935 Hemodialysis | Facility | 25 | 21 | $55.96 | $1,399 |
| 90961 ESRD Related Services (not dialysis) | Office | 21 | 12 | $232.90 | $4,891 |
By year: 2022 $108K for 1,361 services; 2023 $91K for 1,347 services; 2024 $92K for 1,551 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85018 Blood Count | 41 | 12 | $2.13 | $87.4 |
Medicare prescription drug claims, 2024
In 2024, the drug Julie Raggio prescribed most often to Medicare patients was Amlodipine Besylate, with 293 prescriptions and refills. In total Julie Raggio wrote 2,426 Medicare prescriptions that cost $321K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Amlodipine Besylate Generic | 293 | 663 | 90 | $2,281 |
| Losartan Potassium Generic | 145 | 374 | 45 | $1,641 |
| Calcitriol Generic | 123 | 311 | 38 | $1,602 |
| Carvedilol Generic | 117 | 302 | 41 | $1,339 |
| Farxiga Dapagliflozin Propanediol | 112 | 141 | 22 | $77K |
| Lisinopril Generic | 95 | 236 | 33 | $878 |
| Torsemide Generic | 75 | 139 | 24 | $1,563 |
| Jardiance Empagliflozin | 68 | 93 | 15 | $55K |
| Furosemide Generic | 66 | 148 | 23 | $476 |
| Hydralazine Hcl Generic | 65 | 151 | 23 | $834 |
| Famotidine Generic | 63 | 140 | 17 | $682 |
| Olmesartan Medoxomil Generic | 58 | 142 | 18 | $1,668 |
| Potassium Chloride Generic | 57 | 128 | 21 | $1,863 |
| Telmisartan Generic | 57 | 148 | 22 | $1,855 |
| Nifedipine Er Nifedipine | 54 | 121 | 16 | $1,555 |
Brand drugs: 305 claims; generic drugs: 2,121 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Julie Raggio were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.